---
layout: post
title: Salbutamol for Multiple Sclerosis
date: '2010-10-14T10:51:00.000-03:00'
author: Francisco H C Felix
tags:
- farmacologia
- neurology
- pharmacology
modified_time: '2011-03-18T21:31:11.693-03:00'
blogger_id: tag:blogger.com,1999:blog-2993346515708552092.post-7091066453498515260
blogger_orig_url: http://pharmak.blogspot.com/2010/10/salbutamol-for-multiple-sclerosis.html
---

<div xmlns='http://www.w3.org/1999/xhtml'><font size='2' face='verdana, arial, helvetica, sans-serif'><br/>Scientists from Harvard, NIH and Chicago's Northwestern University reported the results of a clinical trial that found albuterol is effective for the treatment of multiple sclerosis patients.<b><br/>Abstract:<br/>Background </b> Interleukin 12 (IL-12), a cytokine that promotes<sup> </sup>generation of helper T cells subtype 1, is increased in multiple<sup> </sup>sclerosis. Albuterol sulfate, a β2-adrenergic agonist,<sup> </sup>reduces IL-12 expression, so we tested the effect of albuterol<sup> </sup>as an add-on treatment to glatiramer acetate therapy.</font><font size='2' face='verdana, arial, helvetica, sans-serif'><b><br/>Objectives </b> To investigate the clinical and immunologic<sup> </sup>effects of albuterol treatment as an add-on therapy in patients<sup> </sup>starting glatiramer acetate treatment.</font><font size='2' face='verdana, arial, helvetica, sans-serif'><b><br/>Design </b> Single-center double-masked clinical trial.</font><font size='2' face='verdana, arial, helvetica, sans-serif'><b><br/>Setting </b> Academic research.</font><font size='2' face='verdana, arial, helvetica, sans-serif'><b><br/>Patients </b> Subjects with relapsing-remitting multiple sclerosis.</font><font size='2' face='verdana, arial, helvetica, sans-serif'><b><br/>Main Outcome Measures </b> In this single-center double-masked<sup> </sup>clinical trial, subjects with relapsing-remitting multiple sclerosis<sup> </sup>were randomized to receive a subcutaneous injection of glatiramer<sup> </sup>acetate (20 mg) plus an oral dose of placebo daily for 2 years<sup> </sup>or a subcutaneous injection of glatiramer acetate (20 mg) plus<sup> </sup>an oral dose of albuterol daily for 2 years. The primary clinical<sup> </sup>efficacy measurement was the change in Multiple Sclerosis Functional<sup> </sup>Composite at 2 years, and the primary immunologic end point<sup> </sup>was the change in expression of IL-13 and interferon <img border='0' alt='{gamma}' src='http://archneur.ama-assn.org/math/gamma.gif'/> at each<sup> </sup>study time point. The classification level of evidence from<sup> </sup>this trial is C for each question, as this is the first class<sup> </sup>II clinical trial addressing the efficacy of glatiramer acetate<sup> </sup>plus albuterol.</font><font size='2' face='verdana, arial, helvetica, sans-serif'><b><br/>Results </b> Forty-four subjects were randomized to receive<sup> </sup>glatiramer acetate plus albuterol or glatiramer acetate plus<sup> </sup>placebo, and 39 subjects contributed to the analysis. Improvement<sup> </sup>in the Multiple Sclerosis Functional Composite was observed<sup> </sup>in the glatiramer acetate plus albuterol group at the 6-month<sup> </sup>(<i>P</i> = .005) and 12-month (<i>P</i> = .04) time points<sup> </sup>but not at the 24-month time point. A delay in the time to first<sup> </sup>relapse was also observed in the glatiramer acetate plus albuterol<sup> </sup>group (<i>P</i> = .03). Immunologically, IL-13 and interferon-<img border='0' alt='{gamma}' src='http://archneur.ama-assn.org/math/gamma.gif'/> production decreased in both treatment groups, and a treatment<sup> </sup>effect on IL-13 production was observed at the 12-month time<sup> </sup>point (<i>P</i> &lt; .05). Adverse events were generally<sup> </sup>mild, and only 3 moderate or severe events were considered related<sup> </sup>to the treatment.</font><font size='2' face='verdana, arial, helvetica, sans-serif'><b><br/>Conclusion </b> Treatment with glatiramer acetate plus albuterol<sup> </sup>is well tolerated and improves clinical outcomes in patients<sup> </sup>with multiple sclerosis.<sup> </sup></font><font size='2' face='verdana, arial, helvetica, sans-serif'><b><br/>Trial Registration </b> clinicaltrials.gov Identifier: <a href='http://clinicaltrials.gov/show/NCT00039988'>NCT00039988</a><br/><br/><b>Complete <a href='http://archneur.ama-assn.org/cgi/content/full/67/9/1055' target='_blank'>here</a>.</b><br/></font></div>